All Clarivate websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.
Kineta Inc., of Seattle, presented preclinical in vitro and animal data at the Novel Antiviral Therapies for Influenza and Other Respiratory Viruses: Bench to Beside Conference in Austin, Texas, from a class of molecules discovered by Kineta and broadly inhibit influenza A and B, respiratory syncytial virus and coronavirus, which include Middle East respiratory syndrome.